Takeda-Abbott Deal Reflects New Realities Facing Japanese Drug Makers
This article was originally published in PharmAsia News
Executive Summary
Takeda's buyout of Abbott Laboratories' half of TAP Pharmaceutical Products reflects a new reality facing Japanese drug makers, according to an analysis. Japan's pharmaceutical business has been hampered by government efforts to lower health care spending at the same time population figures are declining. As a result, drug makers in the country are looking overseas for business expansion. Takeda has stepped up mergers and acquisitions abroad since last year, using the resources of foreign companies to supplant reduced business at home. (Click here for more - a subscription may be required
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.